Summary of significant changes as follows: • Study population – utilisation of official name of response criteria in study; bone marrow cellularity of >15% is only required for those patients randomised to Zevalin. Clarification to Methodology including: • Definition of risk groups • patient population • length of follow-up for safety assessment, • steps in the study, • response criteria to be used in study, • eligibility criteria, • inclusion and exclusion criteria, • description of patient number assignments made which include rationale for inclusion of follicular lymphoma grade 3B • randomisation process prior to study treatment • timeframe for collection of concomitant mediations • timing for screening activities • timing of bone marrow biopsy to confirm complete remission • screening procedures relating to pathology reports and secondary pathology review • Age-adjusted International Prognostic Index • Post-randomisation study procedures for both arms • Evaluation and timing of disease status, including use of MRI and applicability of neck imaging • Follow-up activities • Timing of survival follow-up • Secondary pathology confirmation procedures • Extended screening window for physical exams • Handling of abnormal laboratory values as adverse events • Timing of haematology laboratory testing • Electrolytes measures in serum laboratory testing • Timing of serum chemistry laboratory testing • Changes to study procedures • Method of assessing disease status • Occurrence of secondary malignancies regardless of timing and study arm reported as SAE • Collection of AEs • Timing and reporting of SAEs to Sponsor • Stratification

Summary of significant changes as follows: • WHO classification 2008, as opposed to Revised European American Lymphoma used for confirmatory pathology review • Results updated for zevalin-randomised patients with the most current safety data • Zevalin Regimen scheduled to begin within 12 weeks of first day of last cycle of R-chemotherapy in line with Cheson 2007 response criteria Changes to inclusion criteria: - Confirmatory review was based on secondary reviews - H&E routine stain used for diagnostic purposes - Diagnostic CT scans performed 8 weeks after the first dose of the last cycle of R-chemotherapy. - PET-CT scans carried out in line with Cheson 2007 response criteria - Changes to blood counts monitored in line with standard practice • Changes to exclusion criteria including addition of pregnant and breastfeeding women and clarification of selection criteria • Changes to randomisation criteria in line with Cheson 2007 response criteria • Preparation and release of IMP to be carried out in line with local guidelines and current standard practice • Concomitant therapy updated with the current safety information • Clarification of study and screening procedures in line with Cheson 2007 response criteria • Clarification of study procedures in line with Zevalin regimen patients and evaluation of remission status • Clarification of secondary pathology confirmation • Clarification of screening activities • Change in duration of follow-up of study activities until relapse • Clarification of safety risks in relation to reproductive risks